anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
* Early and late forms of diarrhea can occur. Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. Late diarrhea can be life threatening and should be treated promptly with loperamide. Monitor patients with diarrhea and give fluid and electrolytes as needed. Institute antibiotic therapy if patients develop ileus, fever, or severe neutropenia. Interrupt Irinotecan Hydrochloride Injection and reduce subsequent doses if severe diarrhea occurs [see Dosage and Administration (2.2) and Warnings and Precautions (5.1)]. 
  * Severe myelosuppression may occur [see Warnings and Precautions (5.2)].
Participants randomized to the TWM Intervention will gain access to a website for 150 days. The TWM website includes: peer-to-peer support through a private social network and optimized gaming features; daily SMS communication for medication reminders and mood tracking; medication adherence monitoring; and tailored HIV informational content.
Pediatric group aged 10-18. Same criteria for inclusion and exclusion apply as for the adult group.
Resource priming: Immediately before sessions 1 to 5, therapists have a five-minute conversation about how to implement strengths-based micro-interventions in the forthcoming session. Strengths-based micro-interventions addresses therapists explicit focus on patients' preexisting strengths and abilities, subtle changes and improvements during therapy (potential recources) as well as motivational preparedness, readiness and goals (motivational resources; Grawe, 2006; Flückiger, et al., 2010).
The invention belongs to the technical field of drugs and relates to preparation and an application of a taxane prodrug. The prodrug is prepared from citronellol and an anticancer drug which are joined through a disulfide bond. The anticancer drug is one of paclitaxel and cabazitaxel. A dosage form which is clinically acceptable and capable of being injected or orally taken can be prepared from the prodrug of the anticancer drug and a pharmaceutically acceptable carrier. The dosage form comprises nanoparticles and lipidosome or emulsion. The prodrug and a preparation can obviously improve the activity of the anticancer drug, reduce the toxicity and increase the stability and the targeting property, so that development of the preparation is facilitated.
The relationship between respiratory patterns and cardiovascular variability in healthy persons has been previously studied. However, the impact of SCI on the interrelationships between the respiratory and cardiovascular systems remains relatively unstudied. The loss of autonomic control in SCI may mean that slow breathing has profound effects on cardiovascular variability. Hence, those with SCI may represent a population that could benefit from the potential physiologic effects of numerous yogic-based breathing patterns that can be applied anywhere any time. Hence, it is important to determine if slower breathing patterns can shift the cardiovascular control pattern to-wards important healthful effects. This physiological study will compare the effects of uncontrolled breathing and traditional yogic slow-breathing practices on cardiovascular variability in SCI patients.
Children diagnosed with acute leukemia, undergoing chemotherapy. Patients with acute leukemia will receive intrathecal methotrexate on day 1 plus intravenous vincristine on day 1 plus oral steroid on days 1-5 plus their regularly scheduled and ongoing daily oral 6-mercaptopurine at the start of a maintenance therapy cycle.
This double-blind, randomized, placebo-controlled, 6-month trial evaluated 148 patients (Hoehn & Yahr II-IV) who were not adequately controlled on L-dopa. Patients in this study had a mean disease duration of approximately 9 years, had been exposed to L-dopa for approximately 7 years, and had experienced "on-off" periods with L-dopa therapy. Patients previously receiving stable doses of selegiline, amantadine, and/or anticholinergic agents could continue on these agents during the study. Patients were started at a dose of 0.25 mg 3 times daily of ropinirole hydrochloride and titrated upward by weekly intervals until an optimal therapeutic response was achieved. The maximum dose of study medication was 8 mg 3 times daily. All patients had to be titrated to at least a dose of 2.5 mg 3 times daily. Patients could then be maintained on this dose level or higher for the remainder of the study. Once a dose of 2.5 mg 3 times daily was achieved, patients underwent a mandatory reduction in their L-dopa dose, to be followed by additional mandatory reductions with continued escalation of the dose of ropinirole hydrochloride. Reductions in the dosage of L-dopa were also allowed if patients experienced adverse events that the investigator considered related to dopaminergic therapy. The mean dose attained at study endpoint was 16.3 mg/day. The primary outcome was the proportion of responders, defined as patients who were able both to achieve a decrease (compared to baseline) of at least 20% in their L-dopa dose and a decrease of at least 20% in the proportion of the time awake in the "off" condition (a period of time during the day when patients are particularly immobile), as determined by patient diary. In addition, the mean percent change from baseline in daily L-dopa dose was examined.

At the end of 6 months, 28% of patients treated with ropinirole hydrochloride were classified as responders (based on combined endpoint) while 11% of patients treated with placebo were responders (p = 0.02). Based on the protocol-mandated reductions in L-dopa dosage with escalating doses of ropinirole hydrochloride, patients treated with ropinirole hydrochloride had a 19.4% mean reduction in L-dopa dose while patients treated with placebo had a 3% reduction (p<0.001). L-dopa dosage reduction was also allowed during the study if dyskinesias or other dopaminergic effects occurred. Overall, reduction of L-dopa dose was sustained in 87% of patients treated with ropinirole hydrochloride and in 57% of patients on placebo. On average, the L-dopa dose was reduced by 31% in patients treated with ropinirole hydrochloride.

The mean number of "off" hours per day during baseline was 6.4 hours for patients treated with ropinirole hydrochloride and 7.3 hours for patients treated with placebo. At the end of the 6-month study, patients treated with ropinirole hydrochloride had a mean of 4.9 hours per day of "off" time, while placebo-treated patients had a mean of 6.4 hours per day of "off" time.
OBJECTIVES: The study aims to check whether individual side effects of treatment with TKIs in patients suffering from CML may contribute to the occurrence of anxiety symptoms. In addition, it was decided to check whether there were any relationships between age, gender, duration of treatment, and the intensity of anxiety, divided by the occurrence of individual side effects.
METHODS: The study involved 91 patients and was conducted at the Hematology Clinic of the University Hospital in Krakow. The following questionnaires were used: created by the author, David Goldberg Questionnaire GHQ-28, and the four-dimensional 4DSQ Questionnaire.
RESULTS: The most frequently mentioned side effects of treatment were bone and joint pain, muscle cramps and pain, water retention, and fatigue. The mean duration of the disease was ten years. Our research showed that fatigue, nausea/indigestion, frequent infections, bone and joint pain, abdominal pain, and loss of appetite were the most common side effects of TKI treatment, which resulted in increased anxiety symptoms.
CONCLUSIONS: The work of doctors, psychologists, and pharmaceutical companies on reducing/alleviating side effects may in the future affect a better quality of life for these patients. Early detection of severe anxiety and taking appropriate steps can prevent the emergence of more significant disorders. In addition, several years of attempts to discontinue treatment with some TKIs (imatinib and nilotinib) in patients who achieve a profound molecular response may improve their mental condition.
PURPOSE: To efficiently produce a calcium chloride crystal high in purity and crystallinity by crystallizing a concentrated CaCl2 soln. having a fixed concn. under a specified condition. CONSTITUTION: A calcium chloride soln. of 60-64wt.% concn. is stirred and crystallized at 145-155 deg.C. The stirring crystallization is executed by cooling gradually the soln. while stirring the soln.. A stirring method is not restricted especially if the crystallization is executed surely. But, a rate of stirring is about 50-100rpm preferably if a size of crystal particles is considered. An agitating blade of a stirring vessel may be a general A4 element, but stirring effect is far more increased when the agitating blade is added to more than two stage corresponding to a volume of a crystallizing can. A temp. difference of the calcium chloride soln. and the cooling liq. is within 30 deg.C preferably. A latest cooling temp. of crystallizing liq. is about 40-70 deg.C. In a separating method, a centrifugal separation is better.  An obtained crystal is solidified by drying it until 75-77wt.% CaCl2 content, thereby its solidification due to external pressure is not caused at the time of long term storage.
PROBLEM TO BE SOLVED: To provide the subject new compound produced by culturing a microbial strain beleging to the genus Streptomyces and capable of forming the antitumor substance BE54238, exhibiting proliferation suppressing effect on the tumor cells of mouse and man and useful e.g. as an agent for the treatment of cancer. SOLUTION: This new antitumor substance BE-54238 (and its salt) is expressed by the formula [R1 is H; R2 is CH2 COOX (X is H or a lower alkyl); R1 and R2 may together form O-CO-CH2 ]. The substance exhibits proliferation suppressing effect on mouse and human tumor cells and is useful in the medical field as an agent for the treatment of cancer, etc. The compound can be produced by culturing a microbial strain belonging to the genus Streptomyces and capable of forming the antitumor substance BE-54238 [e.g. Streptomyces sp. A54238 (FREM P-15721)], collecting the culture product from the culture liquid and the microbial cells and optionally converting the compound into a salt.
The invention discloses an external fumigation-washing traditional Chinese medicine for treating traumatic soft tissue ossification and calcification. The external fumigation-washing traditional Chinese medicine has an optimal prescription by weight as follows: 150g of alangium platanifolium, 50g of oblongleaf kadsura stem root, 60g of lycopodium clavatum, 50g of citronella, 5g of daemonorops draco, 55g of sargentgloryvine stem, 100g of premna fulva craib, 55g of buddleja asiatica, 50g of elderberry, and 50g of rhizoma nardostachyos. Medicines in the prescription are divided into crude medicines and processed medicines which are strictly processed to reach a preset efficacy standard and then are integrally grinded into thick powders, and the thick powders are bagged for external use in a fumigation-washing mode only, not for drinking. A patient being subjected to traumatic soft tissue ossification and calcification can be treated with the external fumigation-washing traditional Chinese medicine in a pore penetrating fumigation-washing mode for 30 minutes once and twice each day; and after being used, the external fumigation-washing traditional Chinese medicine can be stored in an original container for next use by being heated. The external fumigation-washing traditional Chinese medicine in the bag can be repeatedly used at three times, and fifteen days are considered as a course. The external fumigation-washing traditional Chinese medicine has no any toxic and side effects and is obvious in curative effect.
1385550 Cholesterol-reducing medicines PHARMACIA AB 2 June 1972 [4 June 1971] 25763/72 Heading ASB [Also in Division C3] Pharmaceutical preparations useful in lowering the cholesterol content of blood comprise polymerisation products containing amino groups which comprise units which are residues of H 2 N . CH 2  . phenylene . CH 2 NH 2  (I) which residues are connected by bridges to form a three dimensional network; the bridges are bound to N atoms in I and comprise straight or branched aliphatic saturated hydrocarbon chains substituted by one or more OH groups and containing 3-30 carbon atoms optionally broken by one or more oxygen atoms. The polymer may exist as the free amine form or may be in the form of a non-toxic salt. The polymer is insoluble in water or other solvents but is capable of swelling in water to gel form, 1g. of the dry product in the form of an HCl salt in the presence of water swelling to at least 5 ml. and at most 50 ml. The polymer is in grain form having particle size 1-1000Á and has an ion-exchange capacity within the range 0.2-1 milliequivalents chloride ions per 100g. of dry gel. Typical examples are prepared by reacting xylylene diamine with epichlorhydrin or with 1, 3-glycerol diglycidyl ether (see Division C3). The products may be administered orally either as such or suspended in liquids or in the form of granulates, tablets or capsules optionally in the presence of physiologically acceptable carriers.
For detailes, please see "Study procedure". Women with newely diagnosed breast cancer are offered written genetic counseling and screening of mutations in BRCA1 and BRCA2.
Patients receive crizotinib PO BID on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
The invention discloses a Chinese medicine composition for treating epicophosis and a preparation method thereof, which belongs to the field of a traditional Chinese medicine. The Chinese medicine composition comprises the following raw materials by weight parts: 13-23 parts of caltrop, 1-5 parts of minium and 4-8 parts of dried orange peel. The preparation method comprises the steps of: weighing the raw materials by weight parts; frying the caltrop to burst; grinding the fried caltrop, the minium and the dried orange peel into powder; and filling the powder in a bottle. The three raw materials restrict and complement each other to take the effects of opening external acoustic meatus, dredging channels and collaterals, promoting blood circulation, activating acoustic nerve cells, and promoting excitation of the acoustic nerve cells. The invention has the advantages of good curative effect, short course of treatment, low cost and easy obtainment of raw materials, convenient use, no toxic and side effect and obvious curative effect on patients with complete eardrum. In 56 clinical cases comprising 24 cases of men and 32 cases of women, wherein the oldest patient is 63 years old and the youngest patient is 8 years old, the total effective rate is 87.6%, and the cure rate is 70.1%.
BACKGROUND: The most common intestinal operation in Crohn's disease (CD) is an ileocolic resection. Despite optimal surgical and medical management, recurrent disease after surgery is common. Different types of anastomoses with respect to configuration and construction can be made after resection for example, handsewn (end-to-end and Kono-S) and stapled (side-to-side). The various types of anastomoses might affect endoscopic recurrence and its assessment, the functional outcome, and costs. The objective of the present study is to compare the three types of anastomoses with respect to endoscopic recurrence at 6 months, gastrointestinal function, and health care consumption.
METHODS: This is a randomized controlled multicentre superiority trial, allocating patients either to side-to-side stapled anastomosis as advised in current guidelines or a handsewn anastomoses (an end-to-end or Kono-S). It is hypothesized that handsewn anastomoses do better than stapled, and end-to-end perform better than the saccular Kono-S. Two international studies with a similar setup will be conducted mainly in the Netherlands (End2End) and Italy (HAND2END). Patients diagnosed with CD, aged over 16 years in the Netherlands and 18 years in Italy requiring (re)resection of the (neo)terminal ileum are eligible. The first part of the study compares the two handsewn anastomoses with the stapled anastomosis. To detect a clinically relevant difference of 25% in endoscopic recurrence, a total of 165 patients will be needed in the Netherlands and 189 patients in Italy. Primary outcome is postoperative endoscopic recurrence (defined as Rutgeerts score ≥ i2b) at 6 months. Secondary outcomes are postoperative morbidity, gastrointestinal function, quality of life (QoL) and costs.
DISCUSSION: The research question addresses a knowledge gap within the general practice elucidating which type of anastomosis is superior in terms of endoscopic and clinical recurrence, functionality, QoL and health care consumption. The results of the proposed study might change current practice in contrast to what is advised by the guidelines.
TRIAL REGISTRATION: NCT05246917 for HAND2END and NCT05578235 for End2End ( http://www.
CLINICALTRIALS: gov/ ).
Trubrexa TM Transdermal Patch is comprised of an adhesive material containing 4.75% lidocaine and 0.025% capsaicin. Each patch is 2 in x 2 in (5.08 cm x 5.08 cm) and consists of an adhesive side containing the active/inactive ingredients and an outer surface backing layer with breathable fabric. The adhesive side is covered with a removable, clear, unprinted, plastic film. The outer surface of the backing layer is imprinted with the Trubrexa TM Transdermal Patch logo. 4 patches are included in each pouch bag. The inactive ingredients include: Arnica, Magnesium, Polyacrylate, Vegan Glycerol, and Water. Trubrexa TM Transdermal Patch is Latex Free, Paraben Free, and Vegan.
If the patient's warfarin consumption dose is more than 5 mg before pregnancy, warfarin dose is decreased to 4 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
Patients will receive applications with the LED board turned off without light activation. Applications will be performed within 1 hour after radiotherapy, three times a week, by a trained team, consisting of physical therapists and physical therapy students, and the application time will be the same as in the intervention group. Women will be instructed to maintain specific home exercises for the upper limbs, which are part of the routine of the physiotherapy sector since the first postoperative day at the HCIII/INCA, in addition to their usual physical activities.
Each participant will receive a comparison pair Prototype dressing (rectangle) vs Marketed dressing (rectangle) applied to knees (one dressing per knee). Each dressing of the comparison pair will be randomised to either the right or left knee in a 1:1 ratio.
PURPOSE:To deposit and separate berberine alkaloid as an ionic salt, by treating a tissue piece or cell of a plant containing the berberine alkaloid with sulfuric acid and adding a salt exchange agent containing chlorine ion, sulfuric acid ion, etc., to the resultant extract solution. CONSTITUTION:A tissue piece or cell of a plant containing berberine alkaloid, e.g. goldthread or Amur cork, is dipped in a 0.2-0.5N aqueous solution of sulfuric acid for >=1hr to give an extract solution. A salt exchange agent, preferably an aqueous solution of hydrochloric acid or nitric acid, containing chlorine ion and/or nitric acid ion is then added to the extract solution to convert the berberine alkaloid into a slightly soluble ionic salt at 10-30 deg.C deposit and separate the berberine alkaloid. EFFECT:The aimed substance is obtained in high purity and recovery ratio by the simple method in a few steps. USE:A medicine for intestinal disorder, remedy for bacterial intestinal diseases and yellowish dyes.
The invention provides a side chain esterified antibacterial peptide WLC6, and a preparation method and application thereof. Side chain esterified antibacterial peptide WLC6 has the sequence WLKKLKKKK (C6) LKLK (C6) KK, wherein C6 is n-hexane acid. The preparation method comprises the following steps: based on a standard alpha helix heptapeptide repetitive sequence 'abcdefg', a basic sequence is designed by using Leu and Lys, and n-hexane acyl modification is carried out on Lys side chains at the 8 th position and the 13 th position to obtain the side chain esterified antibacterial peptide WLC6. The antibacterial peptide WLC6 is applied to the medicine for treating the gram-negative bacteria and/or gram-positive bacteria infectious diseases. The antibacterial agent has high-efficiency antibacterial activity, low hemolytic activity and high salt particle stability, and kills bacteria through a physical membrane breaking mechanism. Has the potential of becoming a high-efficiency antibiotic substitute for treating bacterial infection including drug-resistant bacteria.
Glycemic management for patients with diabetes during hospitalization is highly challenging, especially for those requiring intensive insulin therapy. For those patients, hypoglycemia is a common adverse event, which is associated with adverse clinical outcomes. Bedside capillary point-of-care (POC) glucose monitoring is the standard of care to assess glycemic control in the hospital. However, POC glucose testing only provides glucose measurements at specific time points, leading to missed information important for glycemic control. Continuous glucose monitoring (CGM) measures interstitial glucose every 5 min, thus providing a more complete glycemic profile during a 24 h period compared with standard POC glucose testing.

The cloud-based real-time continuous glucose monitoring (RT-CGM) and management system was previously observed to be safe and effective in guiding intensive insulin therapy. Therefore, this CGM intergraded system holds promise for improving glucose control in patients with diabetes during hospitalization. However, it is currently unclear if alerts are the main reason for the better outcome in the RT-CGM groups, or rather the fact that sensor values are available in real-time. Moreover, the current system provided the feature of predictive threshold alerts that could alert before the onset of clinical hypoglycemia or hyperglycemia. Thus, this trial aims to examine whether these glucose alerts provided added benefit on glycemic outcomes in patients with type 1 or 2 diabetes who required intensive insulin therapy during hospitalization.